| 20th Dec 2018 7:05 am |
RNS |
Lynparza meets primary endpoint in SOLO-3 trial |
| 20th Dec 2018 7:00 am |
RNS |
Phase III ROCKIES and OLYMPUS roxadustat trials |
| 19th Dec 2018 6:31 pm |
RNS |
FDA approves Lynparza as 1L maintenance therapy |
| 18th Dec 2018 9:09 am |
RNS |
Roxadustat approved in China for the treatment of |
| 14th Dec 2018 7:00 am |
RNS |
Directorate Change |
| 7th Dec 2018 7:00 am |
RNS |
Update on the Phase III EAGLE trial of Imfinzi |
| 6th Dec 2018 7:00 am |
RNS |
Divestment of rights to Covis completed |
| 4th Dec 2018 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 3rd Dec 2018 4:00 pm |
RNS |
Block listing Interim Review |
| 3rd Dec 2018 4:00 pm |
RNS |
Total Voting Rights |
| 3rd Dec 2018 7:00 am |
RNS |
Grünenthal Agreement for Nexium, Vimovo Completed |
| 26th Nov 2018 7:00 am |
RNS |
US FDA grants Fasenra ODD for EGPA |
| 16th Nov 2018 7:00 am |
RNS |
AstraZeneca provides update on Phase III MYSTIC |
| 13th Nov 2018 7:00 am |
RNS |
AstraZeneca to divest US Synagis rights to Sobi |
| 12th Nov 2018 7:05 am |
RNS |
US FDA accepts regulatory submission for Lynparza |
| 12th Nov 2018 7:00 am |
RNS |
Farxiga significantly reduced hospitalisation for |
| 8th Nov 2018 7:00 am |
RNS |
AZN: Year-to-Date and Q3 2018 Results |
| 6th Nov 2018 7:00 am |
RNS |
Divestment of rights to Covis Pharma |
| 1st Nov 2018 3:00 pm |
RNS |
Total Voting Rights |
| 31st Oct 2018 9:45 am |
RNS |
Additional financial information-Grünenthal deal |
| 30th Oct 2018 7:00 am |
RNS |
Grünenthal Agreement for rights to Nexium, Vimovo |
| 23rd Oct 2018 7:00 am |
RNS |
AstraZeneca Extends Innate Pharma Collaboration |
| 22nd Oct 2018 7:00 am |
RNS |
Lynparza shows 70% reduction in PFS ovarian cancer |
| 19th Oct 2018 1:09 pm |
RNS |
CHMP positive opinion Bevespi Aerosphere |
| 16th Oct 2018 7:00 am |
RNS |
FDA Orphan Drug for Lynparza in pancreatic cancer |
| 1st Oct 2018 3:00 pm |
RNS |
Total Voting Rights |
| 1st Oct 2018 7:00 am |
RNS |
Atacand Agreement with Cheplapharm Completed |
| 28th Sep 2018 4:00 pm |
RNS |
Previous Announcement Regarding Appointment Of NED |
| 25th Sep 2018 1:15 pm |
RNS |
Overall survival data for Imfinzi: Stage III NSCLC |
| 24th Sep 2018 4:10 pm |
RNS |
EMA approves AZ's Imfinzi for Stage III NSCLC |
| 24th Sep 2018 7:00 am |
RNS |
Farxiga gets positive result in DECLARE-TIMI 58 |
| 14th Sep 2018 7:00 am |
RNS |
FDA approves AZ's Lumoxiti in hairy cell leukaemia |
| 7th Sep 2018 7:00 am |
RNS |
Tezepelumab FDA Breakthrough Therapy Designation |
| 6th Sep 2018 7:00 am |
RNS |
Directorate Change |
| 3rd Sep 2018 3:00 pm |
RNS |
Total Voting Rights |
| 31st Aug 2018 7:00 am |
RNS |
AstraZeneca Update on Anifrolumab in SLE |
| 30th Aug 2018 7:00 am |
RNS |
EC approves Bydureon BCise device for T2 diabetes |
| 23rd Aug 2018 7:00 am |
RNS |
AstraZeneca PIIIb trial update for Bevespi in COPD |
| 21st Aug 2018 7:00 am |
RNS |
AZ's Tagrisso approved in Japan for 1st-line NSCLC |
| 15th Aug 2018 7:00 am |
RNS |
AstraZeneca prices a $3bn bond issue |
